Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: Seeking Alpha
R. Huntsman - Co-Founder, Chairman of the Board & CEO Bradford Amman - CFO, Treasurer & Secretary Jennifer Hauser Conference Call Participants Donna M. Ackerly Presentation R. Huntsman Co-Founder, Chairman of the Board & CEO Good morning. On behalf of our Board of Directors and our officers and employees, I would like to welcome everyone to the 2025 Annual Meeting of Stockholders of Vivos Therapeutics, Inc., which is being held via live webcast. I am Kirk Huntsman, Chief Executive Officer and Chairman of the Board of Directors of Vivos. I will act as Chair of this meeting. Here with me today is Brad Amman, our Chief Financial Officer, Secretary and Treasurer, who will act as the Secretary of the meeting; and Donna Ackerly of Lioness Consulting, our proxy solicitation adviser, who has appointed as the Inspector of Election of this meeting. Also present today in listen-only mode are the members of our Board of Directors as well as many of our employees and our outside
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics (NASDAQ:VVOS) had its price target lowered by analysts at Ascendiant Capital Markets from $6.50 to $5.50. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics (NASDAQ:VVOS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025GlobeNewswire
VVOS
Earnings
- 11/19/25 - Beat
VVOS
Sec Filings
- 11/19/25 - Form 8-K
- 11/19/25 - Form 10-Q
- 11/14/25 - Form NT
- VVOS's page on the SEC website